Background & Summary
====================

Friedreich's ataxia (FRDA) is the most common hereditary ataxia, with elevated differences in symptomatology between individuals and within families. Instability of the GAA expansion size is responsible for approximately 50% of the variability found in disease onset^[@b1]^. Ataxia stems from spinocerebellar degeneration, peripheral sensory neuropathy, and cerebellar and vestibular pathology, and pyramidal disabilities begin to appear after its onset^[@b2]^. Other non-neurological features are related to Friedreich's ataxia. For example, hypertrophic cardiomyopathy, which is the primary cause of death in these patients, is found very often in FRDA patients. Also, diabetes mellitus^[@b3]^ and scoliosis are associated with FRDA^[@b4],[@b5]^.

MicroRNAs (miRNAs) are made up of about 22 nucleotides and are the best-characterized small non-coding RNAs (sncRNAs). There is a continuously increasing number of human transcripts corresponding to miRNAs, and their sequences and annotations have been published^[@b6]^. miRNA can target mRNAs and control their degradation when there is enough complementarity between the two or when translational repression of protein expression ocurrs^[@b7],[@b8]^. Some miRNAs are released from cells in membrane-bound vesicles which protect them from RNase activity^[@b9]^, and for this reason miRNAs can be detected in circulating fluids such as plasma, serum, urine and saliva^[@b10]^. Besides their role in specific tissues, and recently as a stable molecule in circulating fluids^[@b13]^, miRNAs have been proposed as biomarkers for some diseases such as cancer^[@b14],[@b15]^, diabetes^[@b16]^, neurodegenerative diseases^[@b17]^, etc.

A small RNA profiling dataset for FRDA patients and healthy controls was generated to identify different miRNA signatures that could explain physiological and molecular pathways underlying this disease and to help determine the phenotypic variability of patients^[@b18]^. We found different expression profiles of miRNAs (hsa-miR-128-3p, hsa-miR-625-3p, hsa-miR-130b-5p, hsa-miR-151a-5p, hsa-miR-330-3p, hsa-miR-323a-3p, and hsa-miR-142-3p) between samples from patients and samples from healthy subjects. In addition, we found that hsa-miR323a-3p is a biomarker for phenotypic differentiation in FRDA patients suffering from cardiomyopathy. To the best of our knowledge, this data set represents the largest public small RNA-seq data on a cohort of FRDA patients. The potential for identifying miRNA signatures in FRDA goes beyond the discovery of physiological and molecular pathways underlying this disease. Understanding the phenotypic variability of patients is also necessary for designing the most appropriate therapy for each of them, according to their specific pattern of disease progression.

In this study, blood samples of FRDA patients (e.g.; FRDA patients with cardiomyopathy "N+C", FRDA patients with diabetes "N+D", FRDA patients with only neurological features "N") and healthy controls were processed and plasma samples were obtained. Plasma samples were used to purify small RNA fractions, then were used to construct the small RNA-seq libraries, and finally were sequenced using the Illumina HiScanSQ platform ([Figure 1](#f1){ref-type="fig"}). The sequence reads were mapped against the human Hg38 build (UCSC Genome Browser). After that, the intersection between the aligned position of the reads and the miRNA coordinates taken from miRBase v21 was performed. In short, we have provided a small RNA-seq data resource on FRDA patients, which is useful to understand phenotypical variability of the disease. Furthermore, the data resource provides an opportunity to identify the biomarkers of diagnosis, prognosis, and treatment monitoring in FRDA.

Methods
=======

We have already presented some of the methods and tools used in our primary publication^[@b18]^. With this paper, we want to expand our previous descriptions and provide a comprehensive resource for reproducing both the experimental and computational analyses. The experimental and analytical procedure we used is described in [Figure 1](#f1){ref-type="fig"}.

Patient and healthy subject recruitment and clinical features
-------------------------------------------------------------

Patients diagnosed with FRDA without neoplastic diseases or active infection were recruited. Data about age, sex, history of diabetes, cardiopathy, and number of GAA repeats in both alleles were recorded ([Table 1](#t1){ref-type="table"}; *n*=25). The scale for assessment and rating of ataxia (SARA), a neurological examination-based method to assess the disease, was used to measure the clinical severity of the disease^[@b19]^. FRDA patients were enrolled in the study following study approval by the Biomedical Research Ethics Committee (CEIB) of Hospital La Paz (Madrid). Plasma biospecimens from FRDA patients were preserved in a public repository of FRDA in the CIBERER Biobank ([www.ciberer-biobank.es](http://www.ciberer-biobank.es); Spanish Biobank Registry number: 000161X02). Healthy volunteers (*n*=25) with no neoplastic diseases, active infection, cardiomyopathy, heart problems, hypertension, or diabetes were enrolled by the Basque Biobank for Research-OEHUN ([www.biobancovasco.org](http://www.biobancovasco.org)) and by the Biobank for Biomedical Research and Public Health of the Valencian Community (IBSP-CV) through the Spanish National Biobank Network (RNBB 2013/12). The subjects of both groups (healthy volunteers and FRDA patients) were matched by sex and age and were processed identically. The selection process and all experimental methods were carried out in accordance with the relevant clinical guidelines, following standard operation procedures, and with the approval of the ethics and scientific committees. All experimental protocols were approved by the Biomedical Research Ethics Committee (CEIB) of Hospital La Paz (Madrid) and the ethics and scientific committees of the IBSP-CV. Informed consent was obtained from all participants.

Sample collection and small RNA extraction and quantification
-------------------------------------------------------------

Plasma samples were extracted from FRDA patients and healthy participants. For that, blood samples were collected in EDTA tubes and centrifuged at 2500 rpm for 10 min. Once plasma was obtained, each sample was stored at −80 °C until RNA extraction. 500 μL of plasma were used to isolate cell-free total RNA (including miRNAs) using the miRNeasy Serum/Plasma kit (Qiagen, Valencia, CA, USA) following the manufacturer's protocol. The RNA was eluted with 25 μL of RNase-free water. The concentration of cell-free total RNA (including miRNAs) was quantified using NanoDrop ND 2000 UV-spectrophotometer (Thermo Scientific, Wilmington, DE, USA).

Small RNA-seq library preparation and sequencing
------------------------------------------------

Small RNA samples were converted to Illumina sequencing libraries using the NEBNext Multiplex Small RNA Library Prep Set for Illumina (Set 1&2) (New England Biolabs, MA, USA), following the manufacturer's protocol. Briefly, 5′ and 3′ adapters were ligated with small RNA molecules purified from plasma, followed by a cDNA library construction and incorporation of index tags by reverse transcription-PCR (RT-PCR). The products of this RT-PCR were purified using 6% non-denaturing polyacrylamide gel electrophoresis, and then size selection of 145--160 bp fraction was performed. The cDNA library samples were hybridized to a paired end flow cell and individual fragments were clonally amplified by bridge amplification on the Illumina cBot cluster generation. Then, the flow cell was loaded on the HiScanSQ platform and sequenced using Illumina's sequencing by synthesis chemistry, generating 50 bp single end reads.

Pre-processing and processing of the reads
------------------------------------------

The quality of the small RNA libraries was first evaluated using FastQC v0.11.5 software ([Figure 2](#f2){ref-type="fig"}). The most important metrics checked were the overall sequence quality: mean of phred quality per base and per read greater than 30; the GC percentage distribution per read: the data (red curve) is expected to approximately follow the theoretical distribution (blue curve) ([Figure 2c](#f2){ref-type="fig"}). The peaks on the left or on the right side are an indicator of the presence of adapters in the reads. We also checked the presence/absence of overrepresented sequences. Based on the results obtained, the sequence reads were trimmed to remove the following adapter: 5′ AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC- NNNNNN- ATCTCGTATGCCGTCTTCTGCTTG 3′ from each sample. The 6 N's sequence is unique per sample and allows it to be barcoded. After this step, the bases at the end of the sequences with a quality less than 20 were removed. Finally, all the sequences with length less than 18 nucleotides were discarded. These operations were performed using the tool Cutadapt^[@b20]^. The remaining sequences were aligned to the human genome reference (Hg38) from the UCSC Genome Browser. The expression of every miRNA per sample was measured using an annotation file from miRBase (v21). It contained all the mature miRNAs known in humans so far. The alignment and quantification steps were performed using the Subread^[@b21]^ and RSubread^[@b22]^ packages (<http://subread.sourceforge.net/>), respectively.

Differential expression analysis
--------------------------------

### Differential expression analysis between FRDA patients and healthy subjects

Firstly, a differential expression analysis of the miRNAs was performed between patients (*n*=25) and controls (*n*=17). In order to do it, we filtered the miRNAs with less than 1 cpm (counts per million) in 17 samples (the size of the smallest group). Subsequently, we performed a correction of factors using the TMM method^[@b23]^ and calculated the effective library sizes. We also estimated the specific dispersions per miRNA with the quantile-adjusted conditional maximum likelihood (qCML) method^[@b24]^. The differential expression analysis was executed using the exact test^[@b24],[@b25]^. In addition, we carried out a normalization of the original counts estimating the effective library sizes using the geometric mean. The normalized values of the most significant miRNAs (FDR \<1e-4) obtained from the differential expression test were used to assess their correlation. Those miRNAs with a level of correlation lower than 0.7 were used to fit a logistic regression model with LASSO penalty^[@b26]^. In order to select the most important miRNAs of the model, a leave one out cross validation was performed. Those miRNAs that had non-zero coefficients at the value of λ and that gave minimum mean cross-validated error were selected.

### Differential expression analysis between FRDA patients grouped by phenotype

We divided the FRDA patients into 3 subgroups according to their phenotype, considering the features described in [Table 1](#t1){ref-type="table"}. Thus, patients were grouped as 1) patients showing only neurological symptoms (*n*=11); 2) patients showing neurological symptoms "N" and suffering cardiomyopathy "N+C" (*n*=9), and 3) patients showing neurological symptoms and diabetes "N+D" (*n*=6). One FRDA patient with neurologic symptoms additionally showed both comorbidities, cardiomyopathy and diabetes, and thus this patient was classified in both the neurological disorder plus cardiomyopathy (N+C), and neurological disorder plus diabetes (N+D) groups. After this stratification, those miRNAs which did not reach 1 cpm (count per million) in at least 5 samples (size of the smallest group) were filtered out. The data were normalized using the TMM method. Afterwards, a Cox-Reid dispersion^[@b27]^ per miRNA was estimated. To find the differentially expressed miRNAs among the three groups compared, the GLM (generalized linear model) ^[@b25]^ approach was used. Additionally, we performed new analyses taking into account other variables such as age, sex and disease onset. The last variables were organized as a dichotomy variable according to median values: 37 and 13 years, respectively. Finally, we carried out every comparison between the different groups using the GLM approach. All statistical analyses were performed using R software (version 3.2.2) and the following packages: edgeR (version 3.12.0), DESeq (version 1.22.0), caret (version 6.0--58), glmnet (version 2.0-2), ROCR (version 1.0-7).

Data Records
------------

RNA-seq data files in FastQ format were deposited at NCBI Sequence Read Archive (Data Citation 1). This accession contains a total of 42 FastQ files resulting from the single end runs for each of the 42 samples. The FastQ format data serves as the raw data from sequencing, which are subjected to further downstream processing. The processed data were deposited at NCBI Gene Expression Omnibus (Data Citation 2).

Technical Validation
--------------------

### Sequencing quality control

We used FastQC v0.11.5 software to perform quality control assessments of the FastQ files before and after the pre-processing steps (filtering, quality trimming and adapter removal). We analysed several measurements, including the overall sequence quality, the GC percentage distribution (i.e. the proportion of guanine and cytosine bp across the reads) and the presence/absence of overrepresented sequences. A representative summary plot after the pre-processing steps is shown (11_TAGCTT_L005_R1_001). Here, the quality scores per base were high, with a median quality score above 30 suggesting high quality sequences across all bases ([Figure 2a](#f2){ref-type="fig"}). The quality score distribution over all sequences was analyzed to see if a subset of sequences had universally poor quality. The average quality for most sequences was high, with scores above 37, which indicated that a significant proportion of the sequences in a run had overall high quality ([Figure 2b](#f2){ref-type="fig"}). The GC distribution per base over all sequences was examined. Despite the GC composition pattern being more similar to the theoretical distribution after the pre-processing steps, it still had a bias ([Figure 2c](#f2){ref-type="fig"}). In addition, overrepresented sequences were examined. Before the adapter removal, some of them were identified as the Illumina indexed adapters used in the sequencing process. After this step, the adapters were no longer identified but we still had overrepresented sequences, possibly because of highly expressed miRNAs ([Table 2](#t2){ref-type="table"}). All other FastQC files were shown to have similar quality metrics compared to sample (11_TAGCTT_L005_R1_001).

### Real-time qPCR validation of selected miRNAS from Small RNA-seq

Reverse transcription reactions were performed using the TaqMan miRNA Reverse Transcription kit and miRNA-specific stem-loop primers (Part No. 4366597, Applied Biosystems. Inc, CA; USA) and 100 ng of input cell-free RNA in a 20 μL RT reaction. Real-time PCR reactions were performed in triplicate, in scaled-down 10 μL reaction volumes using 5 μL TaqMan 2x Universal PCR Master Mix (Applied Biosystems. Inc, CA; USA) with No UNG, 0.5 μL TaqMan Small RNA assay (20x) (Applied Biosystems. Inc, CA; USA) \[hsa-miR-128-3p (002216), hsa-miR-625-3p (002432), hsa-miR-130b-5p (002114), hsa-miR-151a-5p (002642), hsa-miR-330-3p (000544), hsa-miR-323a-3p (002227), hsa-miR-142-3p (000464), hsa-miR-16-5p (000391)\], 3.5 μL of nuclease free water and 1 μL of RT product. Real-time PCR was carried out on an Applied BioSystems 7900HT thermocycler (Applied Biosystems. Inc, CA; USA) programmed as follows: 50 °C for 2 min, 95 °C for 10 min followed by 45 cycles of 95 °C for 15 s and 60 °C for 1 min. We used hsa-miR-16-5p (000391), one of the most stable miRNAs in terms of read counts, and which has been used previously as an endogenous control^[@b27]^, to normalize the expression in plasma samples. RNU48 (001006), meanwhile, was used to normalize the expression in cell-line samples. All the fold-change data were obtained using the delta-delta CT method (2^−ΔΔCT^)^[@b28]^. The seven differentially expressed miRNAS detected after small RNA-seq were validated using RT-qPCR. All miRNAs were present in plasma at higher levels in patients (*n*=25) compared to healthy controls (*n*=25), in agreement with the results obtained by small RNA-seq. Relative expression levels of the miRNAs in plasma from FRDA patients compared to healthy subjects were shown in Seco-Cervera *et al.*^[@b18]^

Usage Notes
-----------

Before processing the raw reads (Data Citation 1) we performed a visual exploration of them by looking for the adapter used in the sequencing process. We saw adapters ligated to the 5′ end for some reads and to the 3′ end in other reads. Despite expecting to always find it at the 3′ end, the opposite situation can sometimes occur. Therefore, we removed the adapter specifying the -b option in Cutadapt. It indicates to the program that the adapter may appear at the beginning (even degraded), within the read, or at the end of the read (even partially).

The alignment can be performed using standard tools, such as Bowtie2^[@b29]^, STAR^[@b30]^, or Burrows-Wheeler Aligner (BWA)^[@b31]^. In our study, we selected the Subread aligner because it is more accurate and faster than previous aligners (nearly four times as fast as the nearest competitor, Bowtie2)^[@b21]^. Additionally, the parameters needed when mapping miRNA-seq reads have been well documented. On the other hand, although known miRNA sequences from miRbase can be used as a reference, we suggest using the whole human genome. In this way, the reads aligning to miRNA sequences and to many other features in the genome at the same time can be discarded. The quantification of microRNA expression can be performed using tools like bedtools intersect^[@b32]^ or featureCounts^[@b22]^. In this step, it is important to allow multiple hits of each read when mapping, since there are multiple copies of some microRNAs in the genome and if it is not allowed, the results might be misleading, or wrong.

Regarding differential expression analysis, we recommend using the popular R packages EdgeR^[@b25]^ and DESeq^[@b33]^. In the case of using the EdgeR package, it is necessary to filter miRNAs which are not expressed in any condition since they can add some noise to the analysis. Another important aspect to note is the use of an appropriate method according to the different types of comparisons performed. When considering a single study factor, qCML is a good method to estimate the dispersions per miRNA and the exact test to do the differential expression analysis. However, when two or more study factors are included in the analysis, it is highly recommended to estimate dispersions per miRNA with the CR method and to use the likelihood ratio test GLM for differential expression.
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![Overview of the study design.\
Plasma samples from Friedreich's Ataxia (*n*=25) and healthy subjects (*n*=17) were analyzed. FRDA patients were classified into 3 groups: only neurological disorder (N; *n*=11), neurological disorder plus cardiomyopathy (N+C; *n*=9), and neurological disorder plus diabetes (N+D; *n*=6). One FRDA patient with neurologic symptoms additionally showed both comorbidities, cariomyopahty and diabetes, and thus this patient was classified in both neurological disorder plus cardiomyopathy (N+C), and neurological disorder plus diabetes (N+D) groups. Small RNA from the plasma samples of each FRDA patient and healthy subject was isolated and sequenced to obtain a miRNA expression profile. Next, mapping of the sequencing reads provided whole miRNome status of individual samples. Differential miRNA expression between FRDA patients and healthy subjects and within patients was performed to identify the miRNA signatures of FRDA patients and their concomitant diseases.](sdata201821-f1){#f1}

![A representative example of quality control metrics of RNA sequenced reads as indicated by FastQC after the preprocessing steps (sample: 11_TAGCTT_L005_R1_001).\
(**a**) Phred quality score distribution over all reads in each base. (**b**) Quality score distribution over all sequences. (**c**) GC content (%) distribution over all sequences.](sdata201821-f2){#f2}

###### Description of FRDA patients and healthy control samples.

  **ID**   **Sex**   **Age**   **Neuropathy (N)**   **Diabetes (N+D)**   **Cardiopathy (N+C)**   **GAA repetitions (allele 1/allele 2)**   **Raw Data File**
  -------- --------- --------- -------------------- -------------------- ----------------------- ----------------------------------------- -----------------------
  27       FEMALE    26        1                    0                    0                       885/1150                                  27_ACAGTG_L007_R1_001
  38       FEMALE    32        1                    0                    1                       850/850                                   38_CCGTCC_L007_R1_001
  42       FEMALE    68        1                    0                    1                       75/75                                     42_GTGGCC_L007_R1_001
  41       FEMALE    48        1                    0                    0                       250/250                                   41_GTGAAA_L007_R1_001
  2        FEMALE    39        1                    0                    0                       380/912                                   2_CGATGT_L005_R1_001
  6        FEMALE    56        1                    0                    1                       67/450                                    6_GCCAAT_L005_R1_001
  18       FEMALE    38        1                    1                    0                       500/500                                   18_CCGTCC_L005_R1_001
  5        FEMALE    46        1                    0                    0                       720/950                                   5_ACAGTG_L005_R1_001
  25       FEMALE    46        1                    0                    1                       767/767                                   25_GTGGCC_L005_R1_001
  29       MALE      28        1                    0                    0                       112/112                                   29_CGTACG_L005_R1_001
  1        MALE      34        1                    0                    1                       634/967                                   1_ATCACG_L005_R1_001
  4        MALE      35        1                    0                    0                       700/834                                   4_TGACCA_L005_R1_001
  13       MALE      35        1                    0                    0                       985/985                                   13_GGCTAC_L005_R1_001
  30       MALE      32        1                    0                    0                       480/580                                   30_GAGTGG_L005_R1_001
  14       MALE      41        1                    0                    0                       10/100                                    14_CTTGTA_L005_R1_001
  39       FEMALE    49        1                    0                    0                       314/314                                   39_GTAGAG_L007_R1_001
  17       MALE      47        1                    1                    0                       650/850                                   17_ATGTCA_L005_R1_001
  15       MALE      37        1                    0                    0                       912/1080                                  15_AGTCAA_L005_R1_001
  16       MALE      39        1                    1                    0                       600/734                                   16_AGTTCC_L005_R1_001
  3        MALE      52        1                    0                    0                       185/385                                   3_TTAGGC_L005_R1_001
  26       FEMALE    37        1                    0                    1                       350/980                                   26_GCCAAT_L007_R1_001
  40       FEMALE    37        1                    1                    0                       480/580                                   40_GTCCGC_L007_R1_001
  43       MALE      21        1                    1                    1                       25/25                                     43_GTTTCG_L007_R1_001
  37       MALE      19        1                    0                    1                       1050/1185                                 37_ATGTCA_L007_R1_001
  28       FEMALE    29        1                    0                    0                       634/1000                                  28_GTTTCG_L005_R1_001
  33       FEMALE    24        0                    0                    0                       Not referred to                           33_TGACCA_L007_R1_001
  34       FEMALE    33        0                    0                    0                       Not referred to                           34_AGTCAA_L007_R1_001
  49       FEMALE    56        0                    0                    0                       Not referred to                           49_CGATGT_L007_R1_001
  46       FEMALE    53        0                    0                    0                       Not referred to                           46_GGTAGC_L007_R1_001
  47       FEMALE    38        0                    0                    0                       Not referred to                           47_ATCACG_L007_R1_001
  31       FEMALE    44        0                    0                    0                       Not referred to                           31_GGTAGC_L005_R1_001
  35       MALE      30        0                    0                    0                       Not referred to                           35_AGTTCC_L007_R1_001
  10       MALE      32        0                    0                    0                       Not referred to                           10_GATCAG_L005_R1_001
  22       MALE      40        0                    0                    0                       Not referred to                           22_GTGAAA_L005_R1_001
  7        FEMALE    54        0                    0                    0                       Not referred to                           7_CAGATC_L005_R1_001
  20       MALE      47        0                    0                    0                       Not referred to                           20_GTAGAG_L005_R1_001
  21       MALE      39        0                    0                    0                       Not referred to                           21_GTCCGC_L005_R1_001
  9        MALE      51        0                    0                    0                       Not referred to                           9_ACTTGA_L005_R1_001
  11       FEMALE    37        0                    0                    0                       Not referred to                           11_TAGCTT_L005_R1_001
  50       MALE      20        0                    0                    0                       Not referred to                           50_TTAGGC_L007_R1_001
  44       MALE      16        0                    0                    0                       Not referred to                           44_CGTACG_L007_R1_001
  45       FEMALE    31        0                    0                    0                       Not referred to                           45_GAGTGG_L007_R1_001

###### A representative example of quality control metrics of RNA sequenced reads as indicated by FastQC after the preprocessing steps (sample: 11_TAGCTT_L005_R1_001).

  **Sequence**                                         **Count**   **%**    **Possible Source**
  ---------------------------------------------------- ----------- -------- ---------------------------------------------------------
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   1264612     41,255   TruSeq Adapter, Index 10 (100% over 49 bp)
  GGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATGCCGTC   88348       2,882    TruSeq Adapter, Index 10 (100% over 50 bp)
  GGCTGGTCCGATGGTAGTGGGTTATCAGAACTAGATCGGAAGAGCACACG   53404       1,742    No Hit
  TGGAGTGTGACAATGGTGTTTAGATCGGAAGAGCACACGTCTGAACTCCA   24203       0,790    Illumina Multiplexing PCR Primer 2,01 (100% over 29 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTTGCTTATCTCGTATG   18397       0,600    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACCAGCTTATCTCGTATG   9871        0,322    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATTTCGTATG   9035        0,295    TruSeq Adapter, Index 10 (97% over 49 bp)
  AAACCGTTACCATTACTGAGTAGATCGGAAGAGCACACGTCTGAACTCCA   8133        0,265    Illumina Multiplexing PCR Primer 2,01 (100% over 29 bp)
  TCCTGTACTGAGCTGCCCCGAAGATCGGAAGAGCACACGTCTGAACTCCA   7712        0,252    Illumina Multiplexing PCR Primer 2,01 (100% over 29 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTGGCTTATCTCGTATG   7282        0,238    TruSeq Adapter, Index 10 (97% over 49 bp)
  CGCGACCTCAGATCAGACGTGGCGACCCGCTGAATTTAGATCGGAAGAGC   7056        0,230    No Hit
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTATCTTATCTCGTATG   6722        0,219    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTCGCTTATCTCGTATG   6321        0,206    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGCTGGTCCGATGGTAGTGGGTTATCAGAACAGATCGGAAGAGCACACGT   6149        0,201    No Hit
  TGGAGTGTGACAATGGTGTTTGAGATCGGAAGAGCACACGTCTGAACTCC   5977        0,195    Illumina Multiplexing PCR Primer 2,01 (100% over 28 bp)
  AGATCGGAAGAGCACACGTCTAAACTCCAGTCACTAGCTTATCTCGTATG   5902        0,193    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGCTGGTCCGAAGGTAGTGAGTTATCTCAATAGATCGGAAGAGCACACGT   5745        0,187    No Hit
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACGAGCTTATCTCGTATG   5492        0,179    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGGTTATCTCGTATG   5167        0,169    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAGCTCCAGTCACTAGCTTATCTCGTATG   5163        0,168    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGCTGGTCCGATGGTAGTGGGTTATCAGAACCAGATCGGAAGAGCACACG   5022        0,164    No Hit
  AGGTCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   4697        0,153    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTTGGTTATCTCGTATG   4447        0,145    TruSeq Adapter, Index 3 (97% over 37 bp)
  AGATCGGAGGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   4425        0,144    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   4249        0,139    TruSeq Adapter, Index 10 (100% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGATTATCTCGTATG   4222        0,138    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCCGAACTCCAGTCACTAGCTTATCTCGTATG   4136        0,135    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCGCACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   4022        0,131    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTCATCTCGTATG   4015        0,131    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGCCACTAGCTTATCTCGTATG   3997        0,130    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGCTGGTCCGATGGTAGTGGGTTATCAGAACCAGATCGGAAGAGCACACG   5022        0,164    No Hit
  AGGTCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   4697        0,153    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCGGTCACTAGCTTATCTCGTATG   3929        0,128    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGGAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   3835        0,125    TruSeq Adapter, Index 10 (97% over 49 bp)
  GGCTGGTCCGATGGTAGTGGGTTATCAGAACTTAGATCGGAAGAGCACAC   3818        0,125    No Hit
  AGATCGGAAGAGCACACGTCTGAACCCCAGTCACTAGCTTATCTCGTATG   3764        0,123    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGGACTCCAGTCACTAGCTTATCTCGTATG   3725        0,122    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACGCGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   3678        0,120    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGGGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   3599        0,117    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTACCTCGTATG   3477        0,113    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGTTTATCTCGTATG   3275        0,107    TruSeq Adapter, Index 10 (97% over 49 bp)
  AAATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCTTATCTCGTATG   3132        0,102    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAGCCTATCTCGTATG   3129        0,102    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGTCTGAACTCCAGTCACTAACTTATCTCGTATG   3127        0,102    TruSeq Adapter, Index 10 (97% over 49 bp)
  AGATCGGAAGAGCACACGCCTGAACTCCAGTCACTAGCTTATCTCGTATG   3110        0,101    TruSeq Adapter, Index 10 (97% over 49 bp)
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